YaoGeJu

Company directoryChina company filings

Nanjing Cavendish Bio-engineering Technology Co., Ltd.

As of 20 November 2026, for the company name Nanjing Cavendish Bio-engineering Technology Co., Ltd. as recorded, the CDE acceptance records name it as first applicant on 19 records, across 12 drug names; the chemical-drug catalogue lists 17 active records with this name as holder.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/20
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/20.

Drug filings

19 acceptance records as first applicant, grouped into 12 source drug names. Source data as of 2026/11/20.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Nimodipine Injection 1 records · Latest accepted 2024/12/28

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2404613Generic2024/12/28Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanizedCDE ↗
Progesterone Injection 1 records · Latest accepted 2024/12/06

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2404227Generic2024/12/06Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jilin Ao Dong Pharma Group Yan Ji Co., Ltd. romanizedCDE ↗
Metoclopramide Hydrochloride Injection 1 records · Latest accepted 2023/11/21

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2303190Generic2023/11/21Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Zhejiang CDMO Pharmaceutical Co., Ltd.CDE ↗
Arginine and Ibuprofen Granules 3 records · Latest accepted 2023/05/06

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2301222Generic2023/05/06Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
CYHS2301221Generic2023/05/06Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
CYHS2301220Generic2023/05/06Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
Pentoxifylline Injection 1 records · Latest accepted 2023/04/04

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2300961Generic2023/04/04Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yue Xing Pharma Co., Ltd. romanizedCDE ↗
Acetaminophen Injection 2 records · Latest accepted 2023/02/22

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2300609Generic2023/02/22Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanizedCDE ↗
CYHS2300608Generic2023/02/22Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanizedCDE ↗
Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution 1 records · Latest accepted 2023/02/18

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2300568Generic2023/02/18Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
Ambroxol Hydrochloride Oral Solution 1 records · Latest accepted 2023/02/18

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2300569Generic2023/02/18Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
Morinidazole and Sodium Chloride Injection 1 records · Latest accepted 2023/02/11

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2300474Generic2023/02/11Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yue Xing Pharma Co., Ltd. romanizedCDE ↗
Rivaroxaban Tablets 4 records · Latest accepted 2022/10/14

Supplement · 1Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2201884Supplement2022/10/14Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
CYHS2101095Generic2021/04/23Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
CYHS2101094Generic2021/04/23Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
CYHS2100015Generic2021/01/08Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
Eplerenone Tablets 2 records · Latest accepted 2021/12/17

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2102151Generic2021/12/17Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
CYHS2102150Generic2021/12/17Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗
Abiraterone Acetate Tablets 1 records · Latest accepted 2021/09/23

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2101758Generic2021/09/23Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.CDE ↗

Changes in the last 90 days

0 events from 2026/08/23 to 2026/11/20. CDE data as of 2026/11/20; NMPA data as of 2026/11/19.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

0 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/20.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Catalogue holder records

17 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/20. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerNMPA approval no.ApprovedCatalogue category (source text)View source
Nimodipine InjectionNanjing Cavendish Bio-engineering Technology Co., Ltd.Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized国药准字H202657752026/09/02Generic approved under the new chemical-drug registration classificationCDE ↗
黄体酮注射液(II) · No verified English nameNanjing Cavendish Bio-engineering Technology Co., Ltd.Jilin Ao Dong Pharma Group Yan Ji Co., Ltd. romanized国药准字H202654972026/08/04Generic approved under the new chemical-drug registration classificationCDE ↗
左奥硝唑氯化钠注射液 · No verified English nameNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized国药准字H202651642026/07/14Generic approved under the new chemical-drug registration classificationCDE ↗
左奥硝唑氯化钠注射液 · No verified English nameNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized国药准字H202651632026/07/14Generic approved under the new chemical-drug registration classificationCDE ↗
Metoclopramide Hydrochloride InjectionNanjing Cavendish Bio-engineering Technology Co., Ltd.Zhejiang CDMO Pharmaceutical Co., Ltd.国药准字H202546362025/06/24Generic approved under the new chemical-drug registration classificationCDE ↗
Morinidazole and Sodium Chloride InjectionNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yue Xing Pharma Co., Ltd. romanized国药准字H202496242024/12/01Generic approved under the new chemical-drug registration classificationCDE ↗
Arginine and Ibuprofen GranulesNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.国药准字H202490882024/10/16Generic approved under the new chemical-drug registration classificationCDE ↗
Pentoxifylline InjectionNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yue Xing Pharma Co., Ltd. romanized国药准字H202490982024/10/16Generic approved under the new chemical-drug registration classificationCDE ↗
Arginine and Ibuprofen GranulesNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.国药准字H202490862024/10/16Generic approved under the new chemical-drug registration classificationCDE ↗
Arginine and Ibuprofen GranulesNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.国药准字H202490872024/10/16Generic approved under the new chemical-drug registration classificationCDE ↗
Eplerenone TabletsNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.国药准字H202339802023/08/01Generic approved under the new chemical-drug registration classificationCDE ↗
Eplerenone TabletsNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.国药准字H202339742023/08/01Generic approved under the new chemical-drug registration classificationCDE ↗
Abiraterone Acetate TabletsNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.国药准字H202331772023/02/14Generic approved under the new chemical-drug registration classificationCDE ↗
Rivaroxaban TabletsNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.国药准字H202235832022/08/10Generic approved under the new chemical-drug registration classificationCDE ↗
Rivaroxaban TabletsNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.国药准字H202235822022/08/10Generic approved under the new chemical-drug registration classificationCDE ↗
Rivaroxaban TabletsNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.国药准字H202232442022/04/19Generic approved under the new chemical-drug registration classificationCDE ↗
Apixaban TabletsNanjing Cavendish Bio-engineering Technology Co., Ltd.Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.国药准字H202134682021/06/08Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/20.

NameCompany / applicantRegistration numberStatusSource update dateView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/20.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/20
Chemical-drug catalogue
Last successful update: 2026/11/20
API registrations
Last successful update: 2026/11/20
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.